NASH is the advanced stage of fatty liver disease, a condition largely caused by obesity and an unhealthy diet and lifestyle. The condition represents a silent epidemic: a major cause of liver ...

Another recent study comparing 75 patients with NASH treated for 48 weeks with either ... option for patients as an initial step along with diet and exercise to improve insulin sensitivity ...

Belfort et al. randomly assigned 55 patients with biopsy-confirmed NASH and either impaired glucose tolerance or type 2 diabetes to receive a hypocaloric diet plus either pioglitazone (30 mg daily ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...

NASH is a form of non-alcoholic fatty liver disease (NAFLD ... The condition is largely associated with obesity and an unhealthy diet and lifestyle, and is on the rise in industrialised nations ...

As 2025 arrives, experts break down the trending diets, highlighting the science-backed winners, the cautious choices to consider and the fads that might not live up to the hype.

“Today’s approval of Rezdiffra will, for the first time, provide a treatment option for these patients, in addition to diet and exercise.” NASH is a result of the progression of nonalcoholic ...

[18] Enhanced oxidative stress occurs in the liver of patients with NASH, as well as in animal models ... the study were not prescribed any specific diet or enrolled in a weight-reducing program ...